ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ImmuneOnco Biopharmaceuticals (Shanghai)'s long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.01.

ImmuneOnco Biopharmaceuticals (Shanghai)'s long-term debt to total assets ratio increased from Dec. 2022 (0.01) to Dec. 2023 (0.01). It may suggest that ImmuneOnco Biopharmaceuticals (Shanghai) is progressively becoming more dependent on debt to grow their business.

ImmuneOnco Biopharmaceuticals (Shanghai) LT-Debt-to-Total-Asset Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) LT-Debt-to-Total-Asset Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.02

0.01

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	0.02	-	0.01	0.01	0.01

ImmuneOnco Biopharmaceuticals (Shanghai) LT-Debt-to-Total-Asset Calculation

ImmuneOnco Biopharmaceuticals (Shanghai)'s Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	11.37	/	956.608
	=	0.01

ImmuneOnco Biopharmaceuticals (Shanghai)'s Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	11.37	/	956.608
	=	0.01

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ImmuneOnco Biopharmaceuticals (Shanghai) LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines